Bruno Le Maire and Roland Lescure on visit at Groupe Fournier - Thones

Bruno Le Maire and Roland Lescure on visit at Groupe Fournier - Thones

French Minister for the Economy and Finances Bruno Le Maire and French Junior Minister for the Industry Roland Lescure visiting the French company Groupe Fournier in Thones, eastern France, on August 24, 2023. The Groupe Fournier is specialized in made to-measures fittings and manufacturing kitchens and bathrooms. Photo by Pierre Thomas/ABACAPRESS.COM

  • Product Code
  • ILEA001638743
  • Registered date
  • 2023/8/24 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Thomas Pierre/ABACA
  • Media size
  • 5000 × 3333 pixel
  • Resolution
  • 300 dpi
  • Deployment size
  • 12.31(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    King of Morocco Receives French President Macron - Rabat

    King of Morocco Receives French President Macron - Rabat

    French Minister of Agriculture, Food Sovereignty, and Forestry Annie Genevard, French Minister of Economy, Finances and Industry Antoine Armand, French Armies and Former Combatants Minister Sebastien Lecornu, French Foreign and European Affairs Minister Jean-Noel Barrot French Minister of National Education Anne Genetet, French Interior Minister Bruno Retailleau during official ceremony as Morocco's King Mohammed VI receives French President Emmanuel Macron at the Mechouar square, at entrance of the Royal Palace in Rabat, Morocco, on October 28, 2024, on the first day of the French president’s State Visit to the Kingdom. Photo by Ammar Abd Rabbo/ABACAPRESS.COM
      Illustrations Doliprane Sanofi - Lisieux

      Illustrations Doliprane Sanofi - Lisieux

      The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
        Illustrations Doliprane Sanofi - Lisieux

        Illustrations Doliprane Sanofi - Lisieux

        The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
          Illustrations Doliprane Sanofi - Lisieux

          Illustrations Doliprane Sanofi - Lisieux

          The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
            Illustrations Doliprane Sanofi - Lisieux

            Illustrations Doliprane Sanofi - Lisieux

            The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
              Illustrations Doliprane Sanofi - Lisieux

              Illustrations Doliprane Sanofi - Lisieux

              The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
                Illustrations Doliprane Sanofi - Lisieux

                Illustrations Doliprane Sanofi - Lisieux

                The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
                  Illustrations Doliprane Sanofi - Lisieux

                  Illustrations Doliprane Sanofi - Lisieux

                  The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
                    Illustrations Doliprane Sanofi - Lisieux

                    Illustrations Doliprane Sanofi - Lisieux

                    The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM
                      Illustrations Doliprane Sanofi - Lisieux

                      Illustrations Doliprane Sanofi - Lisieux

                      The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM